Evidence map›Paper›PMID 41187099›Full record

ReviewClinical science (London, England : 1979)2025

Complement C3 in panvascular disease: a central integrator of immune signaling and vascular remodeling.

Yu Li, Hesong Zeng, Xiaodan Zhong

Abstract readReview
In one paragraph

Review in Clinical science (London, England : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yu LiDepartment of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Hesong ZengDepartment of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Xiaodan ZhongDepartment of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.ORCID 0000-0001-5268-3905

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Panvascular disease, defined by the systemic involvement of multiple vascular beds, poses a growing challenge to contemporary diagnostic and therapeutic paradigms. Despite organ-specific manifestations, these conditions share a convergent pathological basis driven by chronic low-grade inflammation, immune dysregulation, and maladaptive vascular remodeling. Within this immunovascular interface, complement C3 (C3) has emerged as a pivotal regulator. Positioned at the convergence of the classical, lectin, and alternative complement pathways, C3 integrates systemic immune cues with microenvironmental stimuli to orchestrate endothelial activation, smooth muscle cell phenotypic switching, immune cell recruitment, platelet activation, and fibroinflammatory remodeling. This review provides a comprehensive analysis of C3 biology, including its structural domains, activation cascades, and downstream effector functions. We examine the role of C3 across major vascular cell types, endothelial cells, vascular smooth muscle cells, innate and adaptive immune cells, platelets, and fibroblasts, highlighting how C3 signaling dynamically shapes both acute injury responses and chronic vascular adaptation. In disease-specific contexts, we delineate how C3 contributes to the pathogenesis of atherosclerosis, coronary artery disease, aortic aneurysm and dissection, hypertension, pulmonary arterial hypertension, peripheral vascular disease, stroke, and autoimmune- associated vasculitides. Special emphasis is placed on the dual-phase roles of C3, such as its injuryexacerbating effects in the acute phase of stroke versus its reparative functions in neuroregeneration. Finally, we review emerging therapeutic strategies targeting C3, with a focus on compstatin-based inhibitors, their pharmacological profiles, clinical trial progress, and immunological safety considerations. Collectively, this review reframes C3 as a master orchestrator of panvascular pathology and a promising target for precision immunomodulation across vascular systems.

Indexed as

Complement C3Signal TransductionVascular DiseasesVascular RemodelingAnimalsHumansComplement C3complement C3immune–vascular interactionpanvascular diseasetargeted therapyvascular remodeling

Identifiers

PMID41187099
PMCPMC12687451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.